Last checked at 
14 Dec 2023 07:00
LEI: 549300Q7EXQQH6KF7Z84
14 December 2023
RTW Biotech Opportunities Ltd
Monthly Valuation Update, November Factsheet
+11.9% NAV movement for the month
RTW Biotech Opportunities Ltd (the "Company") announces that the unaudited net asset value attributable to the ordinary shares of the Company at the close of business on 30th November 2023 (the "NAV") was US$347.7 million, or US$1.65 per ordinary share, +11.9% from the previous month.
The monthly factsheet is available on the Company's website:
https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/factsheets-letters/
For Further Information:
RTW Investments, LP | +44 20 7959 6361 |
Woody Stileman, Managing Director Krisha McCune, Director, Client Service |
|
|
|
Buchanan | +44 20 7466 5107 |
Charles Ryland |
|
Henry Wilson |
|
George Beale |
|
|
|
Numis | +44 20 7260 1000 |
Freddie Barnfield |
|
Nathan Brown |
|
Euan Brown |
|
| |
BofA Securities | +44 20 7628 1000 |
Edward Peel |
|
Kieran Millar
|
|
Cadarn Capital |
+44 73 6888 3211 |
David Harris |
|
Elysium Fund Management Limited Joanna Duquemin Nicolle, Chief Executive Officer Sadie Morrison, Managing Director
|
+44 (0) 14 8181 0100 |
Morgan Stanley Fund Services USA LLC | +1 914 225 8885 |
About Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.